Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock remained 8.53million shares. The beta of the stock remained 0.34. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.
Shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) were the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 42,213,990 shares, a growth of 6.4% from the March 31st total of 39,661,474 shares. ARIA has been the subject of a number of recent research reports. Analysts at BMO Capital Markets reiterated a “positive” rating on shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) in a research note on Wednesday, March 26th. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 2.82 percent to $7.47 Thursday on volume of 8.75million shares. The intra-day range of the stock was $7.22 to $7.68. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.39billion.
Shares of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) soared 45.6% after the company announced that the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit against Par Pharmaceuticals, Inc. andImpax Laboratories, Inc. (IPXL – Snapshot Report) in its favor. Par Pharma and Impax Labs had filed abbreviated new drug applications (ANDAs) to get their generic versions of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)’s Nuedexta approved. Avanir Pharmaceuticals Inc (NASDAQ:AVNR)’s stock on May 1, 2014 reported a decrease of -6.63% to the closing price of $4.65. Its fifty two weeks range is $2.62 -$6.00. The total market capitalization recorded $708.18million. The overall volume in the last trading session was 11.68million shares. In its share capital, AVNR has 152.30million outstanding shares.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced promising preclinical results for RX-21101, the Company’s first development candidate derived from its Nano-Polymer-Drug Conjugate System (NPDCS) platform. Results of the study were presented in a poster titled, “Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy,” at the American Association for Cancer Research (AACR) Annual Meeting 2014 held earlier this month. On Thursday, shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) dropped -6.25% to close the day at $0.890. Company monthly performance is recorded as -21.91%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) quarterly revenue growth is -24.56%.